Finance

Lists
ANRO:NYSE
Alto Neuroscience Inc
$23.52
0.00%
(0.00) 1D
Oct 7, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANRO...
Mkt. cap
922.97M
Avg. vol.
562.00K
Volume
74.00
52-wk high
$37.48
52-wk low
$5.22
EPS
-$2.44
Shares outstanding
39.24M
No. of employees
68
Mkt. cap
922.97M
Avg. vol.
562.00K
Volume
74.00
52-wk high
$37.48
52-wk low
$5.22
EPS
-$2.44
Shares outstanding
39.24M
No. of employees
68
News stories
From web sources and news partners
About Alto Neuroscience Inc
CEO-
Employees68
Founded2019
Headquarters-
SectorPharmaceutical industry
Websitealtoneuroscience.com
Analyst ratings
Based on 5 analysts giving stock ratings to ANRO in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ANRO in the last 3 months.
Highest
Current $23.52
$55.00 (+133.84%)
Average
$44.00 (+87.07%)
Lowest
$37.00 (+57.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Myles Minter
William Blair
Buy
Reiterated
-
-
10/02/2026
Patrick Trucchio
H.C. Wainwright
Buy
Maintained
$55.00
+133.8%
09/21/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
08/14/2026
Andrew Tsai
Jefferies
Buy
Maintained
$40.00
+70.1%
08/13/2026
Thomas Shrader
BTIG
Buy
Reiterated
$37.00
+57.3%
08/13/2026
Justin Walsh
JonesTrading
Buy
Reiterated
$44.00
+87.1%
06/26/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$36.00
+53.1%
05/18/2026
Laura Chico
Wedbush
Hold
Maintained
$24.00
+2%
05/14/2026
Ritu Baral
TD Cowen
Buy
Maintained
-
-
05/13/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$30.00
+27.6%
04/21/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$33.00
+40.3%
04/02/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.65 / -$0.77
+15.95%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.52M
12.00M
20.29M
22.11M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.43M
5.06M
6.84M
7.02M
Operating expense
14.95M
17.06M
27.14M
29.13M
Total operating expenses
14.95M
17.06M
27.14M
29.13M
Operating income
-14.95M
-17.06M
-27.14M
-29.13M
Other non operating income
-112.00K
-113.00K
-115.00K
-130.00K
EBT including unusual items
-14.18M
-16.18M
-26.24M
-27.64M
EBT excluding unusual items
-14.18M
-16.18M
-26.24M
-27.64M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14.18M
-16.18M
-26.24M
-27.64M
Net profit margin
-
-
-
-
Earnings per share
-0.52
-0.45
-0.80
-0.65
Interest and investment income
1.53M
1.56M
1.56M
2.11M
Interest expense
-650.00K
-575.00K
-545.00K
-491.00K
Net interest expenses
882.00K
986.00K
1.02M
1.62M
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.79M
-16.90M
-26.95M
-28.94M
Gain or loss from assets sale
114.00K
-
9.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps